Allena Pharmaceuticals, Inc. is a Delaware-incorporated, Sudbury, Massachusetts-based biopharmaceutical company focused on the discovery and development of oral biological therapeutics for rare metabolic and kidney disorders. The company’s research platform produced two primary clinical-stage candidates: Reloxaliase, an enzyme therapeutic for enteric hyperoxaluria, and ALLN-346, a urate-degrading enzyme for hyperuricemia and gout in chronic kidney disease. Allena operates through two subsidiaries, including Allena Pharmaceuticals Ireland Limited.